Volume 22, Issue 2 pp. 147-155

Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction

Thomas A. Fey

Corresponding Author

Thomas A. Fey

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Department 4N5, Bldg. AP9-1, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6118.Search for more papers by this author
Murali Gopalakrishnan

Murali Gopalakrishnan

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
James G. Strake

James G. Strake

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
Linda L. King

Linda L. King

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
Jorge D. Brioni

Jorge D. Brioni

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
James P. Sullivan

James P. Sullivan

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
Michael J. Coghlan

Michael J. Coghlan

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
Michael E. Brune

Michael E. Brune

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Search for more papers by this author
First published: 10 February 2003
Citations: 17

Abstract

Aims

To compare in vivo the efficacy, potency, and bladder–vascular selectivity of ATP-sensitive potassium channel openers (KCOs), YM934 and (-)-cromakalim to a muscarinic antagonist, tolterodine in a novel partial outlet obstructed pig model.

Methods

Partially obstructed female Landrace pigs were implanted with telemetry transmitters to allow the continuous measurement of intravesical, abdominal and arterial pressures. A subcutaneous port catheter was used to adjust bladder volume. Bladder and arterial pressure were simultaneously monitored under isoflurane anesthesia before and after increasing i.v. doses of test compounds.

Results

Under anesthesia, voiding was completely inhibited, but spontaneous, nonvoiding bladder contractions were observed with mean amplitude of 16 ± 1 cm H2O, duration of 35 ± 2 seconds, and intercontraction interval of 43 ± 4 seconds (n = 25). YM934 and (-)-cromakalim both caused dose-dependent decreases in bladder contraction area under the curve (AUC) with effective doses to inhibit AUC by 35% of 3.6 and 14.9 nmol/kg, i.v., respectively. However, concomitant reductions in mean arterial pressure of 12 and 13% were also observed. Tolterodine did not inhibit spontaneous bladder contractions at doses up to 100 nmol/kg, i.v. corresponding to plasma concentrations up to 41 ng/mL.

Conclusions

The superior efficacy of KCOs to inhibit spontaneous bladder contractions relative to tolterodine support the hypothesis that KCOs may provide an alternate therapeutic mechanism to treat symptoms of overactive bladder if bladder-vascular selectivity can be sufficiently improved. The minimally invasive model described herein appears useful in the preclinical evaluation of potential therapeutics targeted to treat the overactive bladder. Neurourol. Urodynam. 22:147–155, 2003. © 2003 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.